NASDAQ:SGEN

Seagen (SGEN) Stock Forecast, Price & News

$213.70

+7.31 (+3.54%)

(As of 09/22/2023 ET)

Compare

Today's Range: $213.20
▼
$214.00
50-Day Range: $191.57
▼
$213.70
52-Week Range: $116.08
▼
$214.00

Volume: 3.16 million shs
Average Volume: 1.35 million shs
Market Capitalization: $40.11 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $190.47

Seagen MarketRank™ Forecast

Analyst Rating: Hold
2.35 Rating Score
Upside/Downside: 10.9% Downside
$190.47 Price Target
Short Interest: Bearish
3.57% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -2.62
Upright™ Environmental Score
News Sentiment: 0.83
Based on 13 Articles This Week
Insider Trading: Selling Shares
$4.91 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($3.40) to ($1.38) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.67 out of 5 stars

Medical Sector

878th out of 968 stocks

Biotechnology Industry

16th out of 22 stocks

1.2

Analyst's Opinion

Consensus Rating
Seagen has received a consensus rating of Hold. The company's average rating score is 2.35, and is based on 6 buy ratings, 11 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $190.47, Seagen has a forecasted downside of 10.9% from its current price of $213.70.
Amount of Analyst Coverage
Seagen has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
3.57% of the outstanding shares of Seagen have been sold short.
Short Interest Ratio / Days to Cover
Seagen has a short interest ratio ("days to cover") of 5.7.
Change versus previous month
Short interest in Seagen has recently increased by 8.06%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Seagen does not currently pay a dividend.
Dividend Growth
Seagen does not have a long track record of dividend growth.

1.9

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Seagen has received a -3.11% net impact score from Upright. The largest negative impact of Seattle Genetics in category "Physical diseases" seems to be driven mostly by its "Brentuximab vedotin", "Enfortumab vedotin", and "Tucatinib" products. See details.
Environmental Sustainability
The Environmental Impact score for Seagen is -2.62.

3.8

News and Social Media Coverage

News Sentiment
Seagen has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 13 news articles for Seagen this week, compared to 5 articles on an average week.
Search Interest
6 people have searched for SGEN on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.
MarketBeat Follows
8 people have added Seagen to their MarketBeat watchlist in the last 30 days. This is an increase of 167% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Seagen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,912,749.00 in company stock.
Percentage Held by Insiders
25.90% of the stock of Seagen is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
84.26% of the stock of Seagen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Seagen are expected to grow in the coming year, from ($3.40) to ($1.38) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Seagen is -54.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Seagen is -54.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Seagen has a P/B Ratio of 14.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Seagen (NASDAQ:SGEN) Stock

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.

SGEN Price History

30 days | 90 days | 365 days | Advanced Chart

SGEN Stock News Headlines

September 22, 2023 | marketbeat.com

Seagen, Activision Blizzard rise; Scholastic, Natural Alternatives fall, Friday, 9/22/2023

Stocks that are trading heavily or have substantial price changes on Friday: Seagen, Activision Blizzard rise; Scholastic, Natural Alternatives fall

September 20, 2023 | marketbeat.com

Flee to Healthcare Stocks if Recession Rears its Head? (SGEN)

In uncertain economic conditions, healthcare stocks can be a refuge due to steady demand and favorable inflation conditions. Many also offer dividends.

September 22, 2023 | Behind the Markets (Ad)

BREAKING: Tiny biotech successfully treats blindness

There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.

September 22, 2023 | investing.com

Seagen gains after 'unsuprising' trial result

September 22, 2023 | msn.com

Why Is Seagen Stock Trading Higher Today?

September 22, 2023 | markets.businessinsider.com

Seagen, Astellas Pharma Report Positive Topline Results From EV-302 Trial

September 22, 2023 | markets.businessinsider.com

Seagen Up In Pre-Market After Positive Results From EV-302 Trial

September 18, 2023 | americanbankingnews.com

Seagen Inc. (NASDAQ:SGEN) Receives Average Rating of "Hold" from Analysts

September 22, 2023 | Behind the Markets (Ad)

BREAKING: Tiny biotech successfully treats blindness

September 16, 2023 | americanbankingnews.com

Seagen (NASDAQ:SGEN) Coverage Initiated by Analysts at StockNews.com

September 12, 2023 | benzinga.com

$1000 Invested In This Stock 15 Years Ago Would Be Worth $16,000 Today

September 12, 2023 | americanbankingnews.com

Investors Buy Large Volume of Seagen Put Options (NASDAQ:SGEN)

September 11, 2023 | msn.com

Nurix (NRIX) Stock Increases 9% in a Month: Here's Why

September 8, 2023 | markets.businessinsider.com

Seagen (SGEN) Gets a Hold from BTIG

September 6, 2023 | businesswire.com

Genmab and Seagen Announce That TIVDAK ® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical ...

August 31, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Seagen (SGEN) and Gain Therapeutics (GANX)

August 25, 2023 | benzinga.com

Here's How Much You Would Have Made Owning Seagen Stock In The Last 10 Years

August 16, 2023 | msn.com

Seagen's Positive Trial Outcomes: Analyst Says The Update Might Double Tukysa's Current Market

August 16, 2023 | reuters.com

Seagen's breast cancer therapy meets main goal in late-stage study

August 16, 2023 | finance.yahoo.com

Seagen Phase 3 Trial of TUKYSA® (tucatinib) in Combination with Antibody-Drug Conjugate ado-trastuzumab emtansine Meets Primary Endpoint of Progression-Free Survival in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer

August 10, 2023 | benzinga.com

If You Invested $100 In This Stock 15 Years Ago, You Would Have $1,600 Today

August 6, 2023 | msn.com

2023 shaping up to be biggest year for biopharma M&A since pandemic

August 4, 2023 | msn.com

Morgan Stanley Reiterates Seagen (SGEN) Equal-Weight Recommendation

August 4, 2023 | markets.businessinsider.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Seagen (SGEN) and Prothena (PRTA)

August 3, 2023 | finance.yahoo.com

Seagen Inc.: Seagen Earnings: Robust Product Sales and Pipeline Advances; Acquisition by Pfizer on Track

August 2, 2023 | finance.yahoo.com

Seattle Genetics (SGEN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

August 2, 2023 | markets.businessinsider.com

Seagen Inc Q2 Loss increases, misses estimates

See More Headlines

Receive SGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Seagen and its competitors with MarketBeat's FREE daily newsletter.

SGEN Company Calendar

Last Earnings: 8/02/2023
Today: 9/22/2023
Next Earnings (Estimated): 10/26/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:SGEN
CUSIP: 81257810
CIK: 1060736
Web: www.seattlegenetics.com
Phone: (425) 527-4000
Fax: 425-527-4001
Employees: 3,256
Year Founded: 1998

Price Target and Rating

Average Stock Price Forecast: $190.47
High Stock Price Forecast: $229.00
Low Stock Price Forecast: $129.00
Forecasted Upside/Downside: -10.9%
Consensus Rating: Hold
Rating Score (0-4): 2.35
Research Coverage: 17 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.89)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-610,310,000.00
Net Margins: -33.54%
Pretax Margin: -32.89%
Return on Equity: -26.46%
Return on Assets: -20.24%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.30
Quick Ratio: 2.66

Sales & Book Value

Annual Sales: $1.96 billion
Price / Sales: 20.44
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $15.10 per share
Price / Book: 14.15

Miscellaneous

Outstanding Shares: 187,700,000
Free Float: 139,084,000
Market Cap: $40.11 billion
Optionable: Optionable
Beta: 0.48

Social Links

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

Mr. David R. Epstein B.Sc. (Age 61)
M.B.A., CEO & Director
Comp: $1.39M

Mr. Todd E. Simpson (Age 62)
Chief Financial Officer
Comp: $1.26M

Dr. Vaughn B. Himes Ph.D. (Age 62)
Chief Technical Officer
Comp: $1.08M

Ms. Jean I. Liu J.D. (Age 55)
M.S., Chief Legal Officer & Corp. Sec.
Comp: $1.23M

Mr. Charles R. Romp (Age 55)
Exec. VP of Commercial U.S.
Comp: $1.08M

Dr. Roger D. Dansey M.D. (Age 67)
Chief Medical Officer and Pres of R&D
Comp: $2.48M

Mr. William Compton
Sr. VP of Global Information Technology & CIO

Mr. David Caouette
VP of Corp. Communications

Mr. Matt Skelton
VP of Marketing

Ms. Peggy M. Pinkston
Chief HR Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

SGEN Stock - Frequently Asked Questions

Should I buy or sell Seagen stock right now?: 17 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Seagen in the last twelve months. There are currently 11 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" SGEN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SGEN, but not buy additional shares or sell existing shares.
View SGEN analyst ratings or view top-rated stocks.
What is Seagen's stock price forecast for 2023?: 17 Wall Street analysts have issued 1-year price objectives for Seagen's shares. Their SGEN share price forecasts range from $129.00 to $229.00. On average, they anticipate the company's stock price to reach $190.47 in the next twelve months. This suggests that the stock has a possible downside of 10.9%.
View analysts price targets for SGEN or view top-rated stocks among Wall Street analysts.
How have SGEN shares performed in 2023?: Seagen's stock was trading at $128.51 at the beginning of 2023. Since then, SGEN stock has increased by 66.3% and is now trading at $213.70.
View the best growth stocks for 2023 here.
When is Seagen's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, October 26th 2023.
View our SGEN earnings forecast.
How were Seagen's earnings last quarter?: Seagen Inc. (NASDAQ:SGEN) released its quarterly earnings results on Wednesday, August, 2nd. The biotechnology company reported ($1.13) EPS for the quarter, missing the consensus estimate of ($0.78) by $0.35. The biotechnology company had revenue of $603.83 million for the quarter, compared to analysts' expectations of $555.68 million. Seagen had a negative trailing twelve-month return on equity of 26.46% and a negative net margin of 33.54%.
What ETFs hold Seagen's stock?: ETFs with the largest weight of Seagen (NASDAQ:SGEN) stock in their portfolio include IQ Merger Arbitrage ETF (MNA), VanEck Biotech ETF (BBH), Invesco Nasdaq Biotechnology ETF (IBBQ), First Trust NYSE Arca Biotechnology Index Fund (FBT), iShares Biotechnology ETF (IBB), AltShares Event-Driven ET (EVNT), Principal Healthcare Innovators ETF (BTEC) and AltShares Merger Arbitrage ETF (ARB).
What is Clay B. Siegall's approval rating as Seagen's CEO?: 107 employees have rated Seagen Chief Executive Officer Clay B. Siegall on Glassdoor.com. Clay B. Siegall has an approval rating of 99% among the company's employees. This puts Clay B. Siegall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Seagen own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Seagen investors own include NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Salesforce (CRM), QUALCOMM (QCOM), Tesla (TSLA), Micron Technology (MU), Netflix (NFLX) and Alibaba Group (BABA).

What is Seagen's stock symbol?: Seagen trades on the NASDAQ under the ticker symbol "SGEN."
Who are Seagen's major shareholders?: Seagen's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.42%), Capital World Investors (4.84%), Capital International Investors (3.42%), State Street Corp (1.78%), Bluefin Capital Management LLC (0.00%) and Bluefin Capital Management LLC (0.00%). Insiders that own company stock include Bros Advisors Lp Baker, Charles R Romp, Charles R Romp, Clay B Siegall, Clay B Siegall, Daniel G Welch, Daniel G Welch, David W Gryska, David W Gryska, Jean I Liu, Jean I Liu, Morgan E Obrien, Roger D Dansey, Roger D Dansey, Todd E Simpson, Todd E Simpson, Vaughn B Himes and Vaughn B Himes.
View institutional ownership trends.
How do I buy shares of Seagen?: Shares of SGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Seagen's stock price today?: One share of SGEN stock can currently be purchased for approximately $213.70.
How much money does Seagen make?: Seagen (NASDAQ:SGEN) has a market capitalization of $40.11 billion and generates $1.96 billion in revenue each year. The biotechnology company earns $-610,310,000.00 in net income (profit) each year or ($3.89) on an earnings per share basis.
How many employees does Seagen have?: The company employs 3,256 workers across the globe.
Does Seagen have any subsidiaries?: The following companies are subsidiares of Seagen: Cascadian Therapeutics.
Read More
How can I contact Seagen?: Seagen's mailing address is 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021. The official website for the company is www.seattlegenetics.com. The biotechnology company can be reached via phone at (425) 527-4000, via email at investors@seagen.com, or via fax at 425-527-4001.

This page (NASDAQ:SGEN) was last updated on 9/22/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial